SOURCE: StockCall

StockCall

July 03, 2012 08:15 ET

Research on Boston Scientific Corp. and Becton, Dickinson and Co. - Obamacare and the Medical Instruments and Supplies Industry

JOHANNESBURG, SOUTH AFRICA--(Marketwire - Jul 3, 2012) -  www.StockCall.com offers free research on Boston Scientific Corporation (NYSE: BSX) and Becton, Dickinson and Company (NYSE: BDX) from the Medical Instruments & Supplies industry. Access these reports by clicking on the links below or by copy and pasting those to your address bar.

www.StockCall.com/reports

For companies in the medical instruments and supplies industry, the effects of the recently upheld healthcare overhaul are still being sorted through. While over 30 million uninsured Americans may become covered, how it will translate into revenues moving forward is unclear.

StockCall.com is an online platform where investors doing their due-diligence on the Medical Instruments & Supplies industry can have easy and free access to our analyst research and opinions on Boston Scientific Corporation and Becton, Dickinson and Company. To see how companies in this industry have grown over the past years and how they are expected to perform in the future, please visit the link below.

www.StockCall.com

Two companies that could be positively affected by the ruling are Boston Scientific Corporation and Becton, Dickinson and Company. Both companies have been making strong moves of their own recently, and a bump from legislation could help push them higher.

Boston Scientific newly announced that it has finished its acquisition of Cameron Health Inc. Through the acquisition Boston Scientific now has the only commercially available subcutaneous implantable cardioverter defibrillator in its product portfolio. Investors and shareholders of Boston Scientific Corporation can simply register for our complimentary reports by clicking on the link below.

www.StockCall.com/BSX030712.pdf

Conversely, Becton Dickenson has also been expanding its portfolio, as it recently announced, through its BD Biosciences segment, the debut of the BD FACSJazz™ Cell Sorting System. The new product is a cutting edge flow cytometer that simplifies cellular isolation and analysis. Register now to have free access to our report on Becton, Dickinson and Company, and to do so please click the link below.

www.StockCall.com/BDX030712.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.

Contact Information